Mountain Crest V (MCAG) to Combine with AUM Biosciences in $400M Deal
Mountain Crest V (NASDAQ:MCAG) has entered into a definitive agreement to combine with biotech firm AUM Biosciences at an equity value of $400 million. Singapore-based AUM is working to develop a range of drugs that could improve the effectiveness of cancer treatments with its most advanced candidates entering Phase II. The combined company is expectedRead More